2 results
Approved WMOCompleted
The objective of this Phase 3 study is to investigate the safety and efficacy of benralizumab as a treatment for patients with eosinophilic esophagitis.
Approved WMORecruiting
To evaluate the effect of benralizumab 100 mg on COPD exacerbations in patients with moderate to very severe COPD.